Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 79 articles:
HTML format
Text format



Single Articles


    September 2017

  1. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed     Text format    


    August 2017
  2. JIAO N, Baker SS, Chapa-Rodriguez A, Liu W, et al
    Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Gut. 2017 Aug 3. pii: gutjnl-2017-314307. doi: 10.1136/gutjnl-2017-314307.
    PubMed     Text format     Abstract available


    July 2017
  3. XIANG DM, Sun W, Ning BF, Zhou TF, et al
    The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Gut. 2017 Jul 28. pii: gutjnl-2016-313392. doi: 10.1136/gutjnl-2016-313392.
    PubMed     Text format     Abstract available


  4. CORRAL JE, Mousa OY, Riegert-Johnson DL
    Massive gastrointestinal bleeding after transjugular intrahepatic portosystemic shunt (TIPS).
    Gut. 2017 Jul 7. pii: gutjnl-2017-314254. doi: 10.1136/gutjnl-2017-314254.
    PubMed     Text format    


  5. ALBANO E, Stickel F
    Targeting toll-like receptor 7/8 improves host anti-infective response in alcoholic cirrhosis.
    Gut. 2017 Jul 7. pii: gutjnl-2017-314437. doi: 10.1136/gutjnl-2017-314437.
    PubMed     Text format    


    June 2017
  6. ROLAS L, Boussif A, Weiss E, Letteron P, et al
    NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation.
    Gut. 2017 Jun 10. pii: gutjnl-2016-313443. doi: 10.1136/gutjnl-2016-313443.
    PubMed     Text format     Abstract available


  7. JIANG RY, Yang L
    The role of hepatokines in NAFLD-related extrahepatic diseases: culprit or accomplice?
    Gut. 2017 Jun 10. pii: gutjnl-2017-314411. doi: 10.1136/gutjnl-2017-314411.
    PubMed     Text format    


  8. LYU N, Lin Y, Kong Y, Zhang Z, et al
    FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314138. doi: 10.1136/gutjnl-2017-314138.
    PubMed     Text format    


  9. WANG Z, Zhang H, Han J, Wu MC, et al
    High body mass index and the risk of hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314259. doi: 10.1136/gutjnl-2017-314259.
    PubMed     Text format    


  10. BAJAJ JS, Liu EJ, Kheradman R, Fagan A, et al
    Fungal dysbiosis in cirrhosis.
    Gut. 2017 Jun 3. pii: gutjnl-2016-313170. doi: 10.1136/gutjnl-2016-313170.
    PubMed     Text format     Abstract available


  11. KULLAK-UBLICK GA, Andrade RJ, Merz M, End P, et al
    Drug-induced liver injury: recent advances in diagnosis and risk assessment.
    Gut. 2017;66:1154-1164.
    PubMed     Text format     Abstract available


  12. ADAMS LA, Anstee QM, Tilg H, Targher G, et al
    Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Gut. 2017;66:1138-1153.
    PubMed     Text format     Abstract available


  13. BROOKS AJ, Smith PJ, Cohen R, Collins P, et al
    UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care.
    Gut. 2017;66:988-1000.
    PubMed     Text format     Abstract available


    May 2017
  14. PANKOWICZ FP, Jarrett KE, Lagor WR, Bissig KD, et al
    CRISPR/Cas9: at the cutting edge of hepatology.
    Gut. 2017 May 9. pii: gutjnl-2016-313565. doi: 10.1136/gutjnl-2016-313565.
    PubMed     Text format     Abstract available


  15. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
    PubMed     Text format    


  16. BREITKOPF-HEINLEIN K, Meyer C, Konig C, Gaitantzi H, et al
    BMP-9 interferes with liver regeneration and promotes liver fibrosis.
    Gut. 2017;66:939-954.
    PubMed     Text format     Abstract available


    April 2017
  17. TRIANTAFYLLOU E, Pop OT, Possamai LA, Wilhelm A, et al
    MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
    Gut. 2017 Apr 27. pii: gutjnl-2016-313615. doi: 10.1136/gutjnl-2016-313615.
    PubMed     Text format     Abstract available


  18. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Text format     Abstract available


  19. HANIN G, Yayon N, Tzur Y, Haviv R, et al
    miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.
    Gut. 2017 Apr 5. pii: gutjnl-2016-312869. doi: 10.1136/gutjnl-2016-312869.
    PubMed     Text format     Abstract available


  20. PARES A
    Juan Rodes. A successful and extraordinary life of a visionary hepatologist.
    Gut. 2017;66:736.
    PubMed     Text format    


  21. LI M, He Y, Zhou Z, Ramirez T, et al
    MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils.
    Gut. 2017;66:705-715.
    PubMed     Text format     Abstract available


  22. HUR K, Toiyama Y, Okugawa Y, Ide S, et al
    Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer.
    Gut. 2017;66:654-665.
    PubMed     Text format     Abstract available


    March 2017
  23. CARLONI V, Lulli M, Madiai S, Mello T, et al
    CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression.
    Gut. 2017 Mar 30. pii: gutjnl-2016-313114. doi: 10.1136/gutjnl-2016-313114.
    PubMed     Text format     Abstract available


  24. HAGSTROM H, Tynelius P, Rasmussen F
    High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.
    Gut. 2017 Mar 20. pii: gutjnl-2016-313622. doi: 10.1136/gutjnl-2016-313622.
    PubMed     Text format     Abstract available


  25. PARSEUS A, Sommer N, Sommer F, Caesar R, et al
    Microbiota-induced obesity requires farnesoid X receptor.
    Gut. 2017;66:429-437.
    PubMed     Text format     Abstract available


    February 2017
  26. PARES A
    Juan Rodes. A successful and extraordinary life of a visionary hepatologist.
    Gut. 2017 Feb 24. pii: gutjnl-2017-313950. doi: 10.1136/gutjnl-2017-313950.
    PubMed     Text format    


  27. VAN RENNE N, Roca Suarez AA, Duong FH, Gondeau C, et al
    miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis.
    Gut. 2017 Feb 3. pii: gutjnl-2016-312270. doi: 10.1136/gutjnl-2016-312270.
    PubMed     Text format     Abstract available


  28. BRUNT EM, Kleiner DE
    Challenges in the hepatic histopathology in non-alcoholic fatty liver disease.
    Gut. 2017 Feb 3. pii: gutjnl-2016-313379. doi: 10.1136/gutjnl-2016-313379.
    PubMed     Text format    


  29. SINN DH, Kang D, Chang Y, Ryu S, et al
    Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.
    Gut. 2017;66:323-329.
    PubMed     Text format     Abstract available


    January 2017
  30. ALVAREZ-SOLA G, Uriarte I, Latasa MU, Fernandez-Barrena MG, et al
    Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration.
    Gut. 2017 Jan 24. pii: gutjnl-2016-312975. doi: 10.1136/gutjnl-2016-312975.
    PubMed     Text format     Abstract available


  31. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed     Text format    


  32. IKENAGA N, Peng ZW, Vaid KA, Liu SB, et al
    Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
    Gut. 2017 Jan 10. pii: gutjnl-2016-312473. doi: 10.1136/gutjnl-2016-312473.
    PubMed     Text format     Abstract available


  33. MAHLI A, Saugspier M, Koch A, Sommer J, et al
    ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis.
    Gut. 2017 Jan 4. pii: gutjnl-2016-312485. doi: 10.1136/gutjnl-2016-312485.
    PubMed     Text format     Abstract available


  34. ROTMAN Y, Sanyal AJ
    Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Gut. 2017;66:180-190.
    PubMed     Text format     Abstract available


  35. LI X, Yao W, Yuan Y, Chen P, et al
    Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Gut. 2017;66:157-167.
    PubMed     Text format     Abstract available


    December 2016
  36. FERNANDEZ-BARRENA MG, Perugorria MJ, Banales JM
    Novel lncRNA T-UCR as a potential downstream driver of the Wnt/beta-catenin pathway in hepatobiliary carcinogenesis.
    Gut. 2016 Dec 16. pii: gutjnl-2016-312899. doi: 10.1136/gutjnl-2016-312899.
    PubMed     Text format    


    November 2016
  37. YU J, Yu XL, Han ZY, Cheng ZG, et al
    Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial.
    Gut. 2016 Nov 24. pii: gutjnl-2016-312629. doi: 10.1136/gutjnl-2016-312629.
    PubMed     Text format    


  38. BOLLARD J, Miguela V, Ruiz de Galarreta M, Venkatesh A, et al
    Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Gut. 2016 Nov 14. pii: gutjnl-2016-312268. doi: 10.1136/gutjnl-2016-312268.
    PubMed     Text format     Abstract available


    September 2016
  39. KUTTKAT N, Mohs A, Ohl K, Hooiveld G, et al
    Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease.
    Gut. 2016 Sep 29. pii: gutjnl-2015-311119. doi: 10.1136/gutjnl-2015-311119.
    PubMed     Text format     Abstract available


  40. DAHEIM M, Lang S, Goeser T, Steffen HM, et al
    Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia.
    Gut. 2016 Sep 26. pii: gutjnl-2016-312993. doi: 10.1136/gutjnl-2016-312993.
    PubMed     Text format    


  41. CAROTENUTO P, Fassan M, Pandolfo R, Lampis A, et al
    Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2016 Sep 12. pii: gutjnl-2016-312278. doi: 10.1136/gutjnl-2016-312278.
    PubMed     Text format     Abstract available


    August 2016
  42. HE GW, Gunther C, Kremer AE, Thonn V, et al
    PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
    Gut. 2016 Aug 26. pii: gutjnl-2015-311247. doi: 10.1136/gutjnl-2015-311247.
    PubMed     Text format     Abstract available



  43. Erratum: Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis.
    Gut. 2016;65:1394.
    PubMed     Text format    


    July 2016
  44. HACKSTEIN CP, Assmus LM, Welz M, Klein S, et al
    Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis.
    Gut. 2016 Jul 18. pii: gutjnl-2015-311224. doi: 10.1136/gutjnl-2015-311224.
    PubMed     Text format     Abstract available


    June 2016
  45. MALLAT A, Lotersztajn S
    Targeting cannabinoid receptors in hepatocellular carcinoma?
    Gut. 2016 Jun 24. pii: gutjnl-2016-312108. doi: 10.1136/gutjnl-2016-312108.
    PubMed     Text format    


  46. BHARDWAJ A, Kedarisetty CK, Vashishtha C, Bhadoria AS, et al
    Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
    Gut. 2016 Jun 13. pii: gutjnl-2016-311735. doi: 10.1136/gutjnl-2016-311735.
    PubMed     Text format     Abstract available


    May 2016
  47. CALO N, Ramadori P, Sobolewski C, Romero Y, et al
    Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption.
    Gut. 2016 May 24. pii: gutjnl-2015-310822. doi: 10.1136/gutjnl-2015-310822.
    PubMed     Text format     Abstract available


  48. NJEI B, McCarty TR, Garcia-Tsao G
    Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters.
    Gut. 2016 May 20. pii: gutjnl-2016-312129. doi: 10.1136/gutjnl-2016-312129.
    PubMed     Text format    


  49. BENOIT B, Pous C
    MAPping the Wnt pathway to hepatocellular carcinoma recurrence.
    Gut. 2016 May 17. pii: gutjnl-2016-311637. doi: 10.1136/gutjnl-2016-311637.
    PubMed     Text format    


  50. SUK KT, Mederacke I, Gwak GY, Cho SW, et al
    Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis.
    Gut. 2016 May 11. pii: gutjnl-2015-310212. doi: 10.1136/gutjnl-2015-310212.
    PubMed     Text format     Abstract available


  51. DUPARC T, Plovier H, Marrachelli VG, Van Hul M, et al
    Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism.
    Gut. 2016 May 5. pii: gutjnl-2015-310904. doi: 10.1136/gutjnl-2015-310904.
    PubMed     Text format     Abstract available


  52. GENTLE L, Patanwala I
    Hepatology at a Glance.
    Gut. 2016 May 4. pii: gutjnl-2016-312068. doi: 10.1136/gutjnl-2016-312068.
    PubMed     Text format    


  53. LLOPIS M, Cassard AM, Wrzosek L, Boschat L, et al
    Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease.
    Gut. 2016;65:830-9.
    PubMed     Text format     Abstract available


    April 2016
  54. O'BRIEN A, China L
    Is human albumin solution really the best resuscitation fluid for patients with advanced cirrhosis?
    Gut. 2016 Apr 27. pii: gutjnl-2016-311999. doi: 10.1136/gutjnl-2016-311999.
    PubMed     Text format    


  55. JANSEN C, Bogs C, Krag A, Francque S, et al
    Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease.
    Gut. 2016 Apr 27. pii: gutjnl-2016-311955. doi: 10.1136/gutjnl-2016-311955.
    PubMed     Text format    


  56. KITSON MT, Pham A, Gordon A, Kemp W, et al
    High-dose vitamin D supplementation and liver histology in NASH.
    Gut. 2016;65:717-8.
    PubMed     Text format    


  57. MICHELOTTI GA, Tucker A, Swiderska-Syn M, Machado MV, et al
    Pleiotrophin regulates the ductular reaction by controlling the migration of cells in liver progenitor niches.
    Gut. 2016;65:683-92.
    PubMed     Text format     Abstract available


    March 2016
  58. PICCININ E, Moschetta A
    Hepatic-specific PPARalpha-FGF21 action in NAFLD.
    Gut. 2016 Mar 18. pii: gutjnl-2016-311408. doi: 10.1136/gutjnl-2016-311408.
    PubMed     Text format    


  59. BRITO-AZEVEDO A, Perez RM, Coelho HS, Fernandes ES, et al
    Propranolol improves endothelial dysfunction in advanced cirrhosis: the 'endothelial exhaustion' hypothesis.
    Gut. 2016 Mar 16. pii: gutjnl-2016-311696. doi: 10.1136/gutjnl-2016-311696.
    PubMed     Text format    


  60. GARCIA-PRAS E, Gallego J, Coch L, Mejias M, et al
    Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension.
    Gut. 2016 Mar 16. pii: gutjnl-2015-311157. doi: 10.1136/gutjnl-2015-311157.
    PubMed     Text format     Abstract available


  61. CHEN J, Rajasekaran M, Xia H, Zhang X, et al
    The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/beta-catenin signalling pathway.
    Gut. 2016 Mar 3. pii: gutjnl-2015-310625. doi: 10.1136/gutjnl-2015-310625.
    PubMed     Text format     Abstract available


  62. KALAMBOKIS GN, Baltayiannis G, Christou L, Christodoulou D, et al
    Red signs and not severity of cirrhosis should determine non-selective beta-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use.
    Gut. 2016 Mar 2. pii: gutjnl-2016-311527. doi: 10.1136/gutjnl-2016-311527.
    PubMed     Text format    


  63. ICHOU L, Carbonell N, Rautou PE, Laurans L, et al
    Ascitic fluid TREM-1 for the diagnosis of spontaneous bacterial peritonitis.
    Gut. 2016;65:536-8.
    PubMed     Text format    


    February 2016
  64. JANSEN C, Bogs C, Verlinden W, Thiele M, et al
    Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study.
    Gut. 2016 Feb 19. pii: gutjnl-2016-311536. doi: 10.1136/gutjnl-2016-311536.
    PubMed     Text format    


  65. COLOMBEL JF, Sands BE, Rutgeerts P, Sandborn W, et al
    The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Gut. 2016 Feb 18. pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079.
    PubMed     Text format     Abstract available


  66. SHI D, Zhang J, Zhou Q, Xin J, et al
    Quantitative evaluation of human bone mesenchymal stem cells rescuing fulminant hepatic failure in pigs.
    Gut. 2016 Feb 16. pii: gutjnl-2015-311146. doi: 10.1136/gutjnl-2015-311146.
    PubMed     Text format     Abstract available


  67. YANG Y, Lin X, Lu X, Luo G, et al
    Interferon-microRNA signalling drives liver precancerous lesion formation and hepatocarcinogenesis.
    Gut. 2016 Feb 9. pii: gutjnl-2015-310318. doi: 10.1136/gutjnl-2015-310318.
    PubMed     Text format     Abstract available


  68. WIESER V, Adolph TE, Enrich B, Kuliopulos A, et al
    Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors.
    Gut. 2016 Feb 8. pii: gutjnl-2015-310344. doi: 10.1136/gutjnl-2015-310344.
    PubMed     Text format     Abstract available


  69. MARCHESI JR, Adams DH, Fava F, Hermes GD, et al
    The gut microbiota and host health: a new clinical frontier.
    Gut. 2016;65:330-9.
    PubMed     Text format     Abstract available


    January 2016
  70. POH Z, Shen L, Yang HI, Seto WK, et al
    Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B.
    Gut. 2016 Jan 19. pii: gutjnl-2015-310818. doi: 10.1136/gutjnl-2015-310818.
    PubMed     Text format    


  71. TILG H, Mathurin P
    Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis.
    Gut. 2016 Jan 19. pii: gutjnl-2015-311014. doi: 10.1136/gutjnl-2015-311014.
    PubMed     Text format    


  72. STOCKDALE AJ, Phillips RO, Geretti AM
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: 'The gamma-glutamyl transpeptida
    Gut. 2016 Jan 4. pii: gutjnl-2015-311133. doi: 10.1136/gutjnl-2015-311133.
    PubMed     Text format    


    December 2015
  73. GARNELO M, Tan A, Her Z, Yeong J, et al
    Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma.
    Gut. 2015 Dec 15. pii: gutjnl-2015-310814. doi: 10.1136/gutjnl-2015-310814.
    PubMed     Text format     Abstract available


  74. TOVAR V, Cornella H, Moeini A, Vidal S, et al
    Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Gut. 2015 Dec 11. pii: gutjnl-2015-309501. doi: 10.1136/gutjnl-2015-309501.
    PubMed     Text format     Abstract available


  75. HU HH, Liu J, Lin YL, Luo WS, et al
    The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2015 Dec 7. pii: gutjnl-2015-310686. doi: 10.1136/gutjnl-2015-310686.
    PubMed     Text format     Abstract available


    October 2015
  76. FLECKEN T, Sarobe P
    Tim-3 expression in tumour-associated macrophages: a new player in HCC progression.
    Gut. 2015;64:1502-3.
    PubMed     Text format    


  77. YAN W, Liu X, Ma H, Zhang H, et al
    Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages.
    Gut. 2015;64:1593-604.
    PubMed     Text format     Abstract available


    September 2015
  78. KLEIN S, Rick J, Lehmann J, Schierwagen R, et al
    Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Gut. 2015 Sep 17. pii: gutjnl-2015-309600. doi: 10.1136/gutjnl-2015-309600.
    PubMed     Text format     Abstract available


    February 2015
  79. ARABZADEH A, Dupaul-Chicoine J, Breton V, Haftchenary S, et al
    Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.
    Gut. 2015 Feb 9. pii: gutjnl-2014-308781. doi: 10.1136/gutjnl-2014-308781.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: